ARS Pharmaceuticals (SPRY) Profit After Tax (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Profit After Tax of -$60.6 million for Q1 2026, down 46.35% sequentially from -$41.4 million in Q4 2025, and down 78.6% YoY from -$283.3 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Profit After Tax (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Profit After Tax for 7 years, with the latest figure at -$60.6 million in Q1 2026.
- Quarterly Profit After Tax fell 78.6% year-over-year to -$60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.1 million (down 1219.59% YoY) and the FY2025 annual result came in at -$171.4 million, down 2198.09% from the prior year.
- Profit After Tax retreated to -$60.6 million in Q1 2026 per SPRY's latest filing, from -$41.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at $50.1 million in Q4 2024 and troughed at -$60.6 million in Q1 2026.
- A 5-year average of -$18.4 million and a median of -$14.9 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 799.01% in 2024, then sank 258.95% in 2025.
- Over 5 years, Profit After Tax stood at -$14.4 million in 2022, then surged by 50.32% to -$7.2 million in 2023, then surged by 799.01% to $50.1 million in 2024, then tumbled by 182.66% to -$41.4 million in 2025, then plunged by 46.35% to -$60.6 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$60.6 million, -$41.4 million, and -$51.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -62.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.38 Mn |
| Mar 31, 2026 | -60.62 Mn |
| Dec 31, 2025 | -41.42 Mn |
| Sep 30, 2025 | -51.11 Mn |
| Jun 30, 2025 | -45.00 Mn |
| Mar 31, 2025 | -33.94 Mn |
| Dec 31, 2024 | 50.11 Mn |
| Sep 30, 2024 | -18.64 Mn |
| Jun 30, 2024 | -12.54 Mn |
| Mar 31, 2024 | -10.47 Mn |
| Dec 31, 2023 | -7.17 Mn |
| Sep 30, 2023 | -14.87 Mn |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -15.30 Mn |
| Dec 31, 2022 | -14.43 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -6.42 Mn |
| Mar 31, 2022 | -7.25 Mn |
| Dec 31, 2021 | 45.81 Mn |
| Sep 30, 2021 | -22.69 Mn |